Genetic Variability of AdeRS Two-Component System Associated with Tigecycline Resistance in XDR-Acinetobacter baumannii Isolates

Current Microbiology

Volumn 71, Issue 1, 2015, Pages 76-82

  Montana S ^a   Vilacoba, E ^a   Traglia, G M ^a   Almuzara, M ^b   Pennini, M ^c   Fernandez A ^d   Sucari, A ^c   Centron D ^a   Ramirez M S ^a,e  

^a UNIVERSIDAD DE BUENOS AIRES   (Argentina)

^b Hospital Eva Peron   (Argentina)

^c Centro Stamboulian   (Argentina)

^d HOSPITAL UNIVERSITARIO FUNDACIÓN FAVALORO   (Argentina)

^e CALIFORNIA STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADER PROTEIN; ADES PROTEIN; BACTERIAL PROTEIN; TIGECYCLINE; UNCLASSIFIED DRUG; ANTIINFECTIVE AGENT; BACTERIAL DNA; MINOCYCLINE;

ACINETOBACTER BAUMANNII; ALLELE; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM ISOLATE; GENETIC VARIABILITY; NONHUMAN; NUCLEOTIDE SEQUENCE; OPERON; PHENOTYPE; PRIORITY JOURNAL; ACTIVE TRANSPORT; ANALOGS AND DERIVATIVES; CHEMISTRY; DNA SEQUENCE; DRUG EFFECTS; GENETICS; MOLECULAR GENETICS; MULTIDRUG RESISTANCE; SIGNAL TRANSDUCTION;

ACINETOBACTER BAUMANNII;

ACINETOBACTER BAUMANNII; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BIOLOGICAL TRANSPORT, ACTIVE; DNA, BACTERIAL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GENETIC VARIATION; MINOCYCLINE; MOLECULAR SEQUENCE DATA; SEQUENCE ANALYSIS, DNA; SIGNAL TRANSDUCTION;

EID: 84930417546     PISSN: 03438651     EISSN: 14320991     Source Type: Journal    
DOI: 10.1007/s00284-015-0829-3     Document Type: Article

References (23)

1. Bonnin RA, Nordmann P, Poirel L (2013) Screening and deciphering antibiotic resistance in Acinetobacter baumannii: a state of the art. Expert Rev Anti Infect Ther 11(6):571–583. doi:10.1586/eri.13.38
2. Chen YH, Ko WC, Hsueh PR (2013) Emerging resistance problems and future perspectives in pharmacotherapy for complicated urinary tract infections. Expert Opin Pharmacother 14(5):587–596. doi:10.1517/14656566.2013.778827
3. Coyne S, Courvalin P, Perichon B (2011) Efflux-mediated antibiotic resistance in Acinetobacter spp. Antimicrob Agents Chemother 55(3):947–953. doi:10.1128/AAC.01388-10
4. Deng M, Zhu MH, Li JJ, Bi S, Sheng ZK, Hu FS, Zhang JJ, Chen W, Xue XW, Sheng JF, Li LJ (2014) Molecular epidemiology and mechanisms of tigecycline resistance in clinical isolates of Acinetobacter baumannii from a Chinese university hospital. Antimicrob Agents Chemother 58(1):297–303. doi:10.1128/AAC.01727-13
5. De Pascale G, Montini L, Pennisi M, Bernini V, Maviglia R, Bello G, Spanu T, Tumbarello M, Antonelli M (2014) High dose tigecycline in critically ill patients with severe infections due to multidrug-resistant bacteria. Crit Care 18(3):R90. doi:10.1186/cc13858
6. Dinc G, Demiraslan H, Elmali F, Ahmed SS, Metan G, Alp E, Doganay M (2013) Efficacy of sulbactam and its combination with imipenem, colistin and tigecycline in an experimental model of carbapenem-resistant Acinetobacter baumannii sepsis. Chemotherapy 59(5):325–329. doi:10.1159/000356755
7. Falagas ME, Bliziotis IA, Siempos II (2006) Attributable mortality of Acinetobacter baumannii infections in critically ill patients: a systematic review of matched cohort and case-control studies. Crit Care 10(2):R48. doi:10.1186/cc4869
8. Hagihara M, Housman ST, Nicolau DP, Kuti JL (2014) In vitro pharmacodynamics of polymyxin B and tigecycline alone and in combination against carbapenem-resistant Acinetobacter baumannii. Antimicrob Agents Chemother 58(2):874–879. doi:10.1128/AAC.01624-13
9. He C, Xie Y, Fan H, Kang M, Tao C, Zhang R, Hu Y, Chen Z, Wang L (2011) Spread of imipenem-resistant Acinetobacter baumannii of European clone II in Western China. Int J Antimicrob Agents 38(3):257–260. doi:10.1016/j.ijantimicag.2011.04.015
10. Higgins PG, Schneiders T, Hamprecht A, Seifert H (2010) In vivo selection of a missense mutation in adeR and conversion of the novel blaOXA-164 gene into blaOXA-58 in carbapenem-resistant Acinetobacter baumannii isolates from a hospitalized patient. Antimicrob Agents Chemother 54(12):5021–5027. doi:10.1128/AAC.00598-10
11. Kim NH, Hwang JH, Song KH, Choe PG, Kim ES, Park SW, Kim HB, Kim NJ, Park WB, Oh MD (2013) Tigecycline in carbapenem-resistant Acinetobacter baumannii bacteraemia: susceptibility and clinical outcome. Scand J Infect Dis 45(4):315–319. doi:10.3109/00365548.2012.732705
12. Kwon SH, Ahn HL, Han OY, La HO (2014) Efficacy and safety profile comparison of colistin and tigecycline on the extensively drug resistant Acinetobacter baumannii. Biol Pharm Bull 37(3):340–346
13. Liao CH, Kung HC, Hsu GJ, Lu PL, Liu YC, Chen CM, Lee CM, Sun W, Jang TN, Chiang PC, Cheng YJ, Lin HC, Shi ZY, Wang LS, Chuang YC, Tsao SM, Lu CT, Liu JW, Huang CH, Hsueh PR (2008) In-vitro activity of tigecycline against clinical isolates of Acinetobacter baumannii in Taiwan determined by the broth microdilution and disk diffusion methods. Int J Antimicrob Agents 32(Suppl 3):S192–S196. doi:10.1016/S0924-8579(08)70027-X
14. Liu JW, Jang TN, Cheng YJ, Hsu GJ, Sun W, Lu CT, Hsueh PR (2010) Comparison of the Etest and broth microdilution method for tigecycline susceptibility testing against clinical isolates of Acinetobacter baumannii from Taiwan. Int J Antimicrob Agents 35(2):201–202. doi:10.1016/j.ijantimicag.2009.09.019
15. Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, Harbarth S, Hindler JF, Kahlmeter G, Olsson-Liljequist B, Paterson DL, Rice LB, Stelling J, Struelens MJ, Vatopoulos A, Weber JT, Monnet DL (2012) Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. Clin Microbiol Infect 18(3):268–281. doi:10.1111/j.1469-0691.2011.03570.x
16. Marchand I, Damier-Piolle L, Courvalin P, Lambert T (2004) Expression of the RND-type efflux pump AdeABC in Acinetobacter baumannii is regulated by the AdeRS two-component system. Antimicrob Agents Chemother 48(9):3298–3304. doi:10.1128/AAC.48.9.3298-3304.2004
17. Ni W, Cai X, Liang B, Cai Y, Cui J, Wang R (2014) Effect of proton pump inhibitors on in vitro activity of tigecycline against several common clinical pathogens. PLoS One 9(1):e86715. doi:10.1371/journal.pone.0086715
18. Stietz MS, Ramirez MS, Vilacoba E, Merkier AK, Limansky AS, Centron D, Catalano M (2013) Acinetobacter baumannii extensively drug resistant lineages in Buenos Aires hospitals differ from the international clones I-III. Infect Genet Evol 14:294–301. doi:10.1016/j.meegid.2012.12.020
19. Sun JR, Chan MC, Chang TY, Wang WY, Chiueh TS (2010) Overexpression of the adeB gene in clinical isolates of tigecycline-nonsusceptible Acinetobacter baumannii without insertion mutations in adeRS. Antimicrob Agents Chemother 54(11):4934–4938. doi:10.1128/AAC.00414-10
20. Traglia GM, Almuzara M, Merkier AK, Papalia M, Galanternik L, Radice M, Vay C, Centron D, Ramirez MS (2013) Distribution of allelic variants of the chromosomal gene bla OXA-114-like in Achromobacter xylosoxidans clinical isolates. Curr Microbiol 67(5):596–600. doi:10.1007/s00284-013-0407-5
21. Viehman JA, Nguyen MH, Doi Y (2014) Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs. doi:10.1007/s40265-014-0267-8
22. Yang JY, Brooks S, Meyer JA, Blakesley RR, Zelazny AM, Segre JA, Snitkin ES (2013) Pan-PCR, a computational method for designing bacterium-typing assays based on whole-genome sequence data. J Clin Microbiol 51(3):752–758. doi:10.1128/JCM.02671-12
23. Zarrilli R, Pournaras S, Giannouli M, Tsakris A (2013) Global evolution of multidrug-resistant Acinetobacter baumannii clonal lineages. Int J Antimicrob Agents 41(1):11–19. doi:10.1016/j.ijantimicag.2012.09.008